A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs
SUZHOU,China,Nov. 13,2024-- Alphamab Oncology (stock code: 9966.HK) announced that a clinical trial (Study ID: JSKN033-102) of JSKN033,a high-concentration subcutaneous co-formulation consisting of an